(RX) Biosyent - Ratings and Ratios

BioSyent Inc. (V:RX) is a Canadian pharmaceutical company specializing in the acquisition, licensing, development, and distribution of healthcare products. Its product portfolio focuses on therapeutic and supplementary solutions, addressing conditions such as iron deficiency anemia, menopausal symptoms, and pain management. Key offerings include FeraMAX Pd, a line of iron deficiency treatments available in therapeutic, maintenance, and powder forms; Tibella, a hormone replacement therapy; Inofolic, a natural health product for polycystic ovarian syndrome; and RepaGyn, a vaginal suppository for menopause-related dryness. The company also provides Gelclair for oral mucositis, Cathejell for urethral lubrication, Combogesic for pain relief, and Proktis-M for rectal healing. Products are distributed through wholesalers and retail pharmacies.

Founded in 2006 and headquartered in Mississauga, Canada, BioSyent Inc. operates under the ticker symbol RX on the TSX Venture Exchange. The company’s market capitalization is approximately 125.05M CAD, with a price-to-earnings ratio of 18.48 and a forward P/E of 13.87, indicating moderate valuation. Its return on equity stands at 19.03%, reflecting efficient profitability. The stock currently trades at 10.88 CAD, with short-term moving averages (SMA 20 and SMA 50) slightly above the last price, suggesting near-term resistance levels.